BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38211900)

  • 1. Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts' position paper.
    Fassan M; Angerilli V; Normanno N; Pruneri G; Marchetti A; Grillo F; Tonini G; Scarpa A; Rimassa L
    Crit Rev Oncol Hematol; 2024 Feb; 194():104224. PubMed ID: 38211900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel insights into molecular and immune subtypes of biliary tract cancers.
    Bramel ER; Sia D
    Adv Cancer Res; 2022; 156():167-199. PubMed ID: 35961699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapies in advanced biliary tract cancers-a narrative review.
    LaPelusa M; Heumann T; Goff L; Agarwal R
    Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
    Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
    JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Ancillary Techniques in Biliary Cytopathology Specimens.
    Layfield L
    Acta Cytol; 2020; 64(1-2):175-181. PubMed ID: 31121596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.
    Wardell CP; Fujita M; Yamada T; Simbolo M; Fassan M; Karlic R; Polak P; Kim J; Hatanaka Y; Maejima K; Lawlor RT; Nakanishi Y; Mitsuhashi T; Fujimoto A; Furuta M; Ruzzenente A; Conci S; Oosawa A; Sasaki-Oku A; Nakano K; Tanaka H; Yamamoto Y; Michiaki K; Kawakami Y; Aikata H; Ueno M; Hayami S; Gotoh K; Ariizumi SI; Yamamoto M; Yamaue H; Chayama K; Miyano S; Getz G; Scarpa A; Hirano S; Nakamura T; Nakagawa H
    J Hepatol; 2018 May; 68(5):959-969. PubMed ID: 29360550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma.
    Madoff DC; Abi-Jaoudeh N; Braxton D; Goyal L; Jain D; Odisio BC; Salem R; Schattner M; Sheth R; Li D
    Oncologist; 2022 Oct; 27(10):884-891. PubMed ID: 35925597
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Angerilli V; Fornaro L; Pepe F; Rossi SM; Perrone G; Malapelle U; Fassan M
    Pathologica; 2023 Apr; 115(2):71-82. PubMed ID: 37017301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How I treat biliary tract cancer.
    Lamarca A; Edeline J; Goyal L
    ESMO Open; 2022 Feb; 7(1):100378. PubMed ID: 35032765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
    Rizzato M; Brignola S; Munari G; Gatti M; Dadduzio V; Borga C; Bergamo F; Pellino A; Angerilli V; Mescoli C; Guido M; Rearden J; Gringeri E; Cillo U; Dei Tos AP; Zagonel V; Loupakis F; Lonardi S; Fassan M
    Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational spectrum and precision oncology for biliary tract carcinoma.
    Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
    Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
    [No Abstract]   [Full Text] [Related]  

  • 13. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
    Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Will advanced cholangiocarcinoma become a targetable malignancy?
    Sarkis Y; Al Soueidy A; Kourie HR
    Crit Rev Oncol Hematol; 2021 Mar; 159():103233. PubMed ID: 33482346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns.
    Israel MA; Danziger N; McGregor KA; Murugesan K; Gjoerup O; Sokol ES; Tukachinsky H; Kurzrock R; Kato S; Sicklick JK; Nimeiri HS; Oxnard GR; Ross JS
    Oncologist; 2021 Sep; 26(9):787-796. PubMed ID: 34080753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
    Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cytomorphologic and Molecular Assessment of Bile Duct Brushing Specimens.
    Hilburn CF; Pitman MB
    Surg Pathol Clin; 2022 Sep; 15(3):469-478. PubMed ID: 36049829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
    Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
    Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing.
    Stenzinger A; Vogel A; Lehmann U; Lamarca A; Hofman P; Terracciano L; Normanno N
    Cancer Treat Rev; 2024 Jan; 122():102649. PubMed ID: 37984132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomics driven precision oncology in advanced biliary tract cancer improves survival.
    Kumar-Sinha C; Vats P; Tran N; Robinson DR; Gunchick V; Wu YM; Cao X; Ning Y; Wang R; Rabban E; Bell J; Shankar S; Mannan R; Zhang Y; Zalupski MM; Chinnaiyan AM; Sahai V
    Neoplasia; 2023 Aug; 42():100910. PubMed ID: 37267699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.